JP2023531069A - アミロイドβ１－４２に結合する抗体を使用する軸索損傷の予防 - Google Patents

アミロイドβ１－４２に結合する抗体を使用する軸索損傷の予防 Download PDF

Info

Publication number
JP2023531069A
JP2023531069A JP2022580122A JP2022580122A JP2023531069A JP 2023531069 A JP2023531069 A JP 2023531069A JP 2022580122 A JP2022580122 A JP 2022580122A JP 2022580122 A JP2022580122 A JP 2022580122A JP 2023531069 A JP2023531069 A JP 2023531069A
Authority
JP
Japan
Prior art keywords
patient
binding member
tau
csf
nfl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531069A5 (enExample
Inventor
タン，キース
シェアリング，クレイグ
アール． シムズ，ジョン
エル． デイジ，ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2023531069A publication Critical patent/JP2023531069A/ja
Publication of JP2023531069A5 publication Critical patent/JP2023531069A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022580122A 2020-06-25 2021-06-25 アミロイドβ１－４２に結合する抗体を使用する軸索損傷の予防 Pending JP2023531069A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043872P 2020-06-25 2020-06-25
US63/043,872 2020-06-25
PCT/EP2021/067536 WO2021260193A1 (en) 2020-06-25 2021-06-25 Prevention of axonal damage using antibody binding to amyloid beta 1-42

Publications (2)

Publication Number Publication Date
JP2023531069A true JP2023531069A (ja) 2023-07-20
JP2023531069A5 JP2023531069A5 (enExample) 2024-07-01

Family

ID=76662499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580122A Pending JP2023531069A (ja) 2020-06-25 2021-06-25 アミロイドβ１－４２に結合する抗体を使用する軸索損傷の予防

Country Status (11)

Country Link
US (1) US20230287092A1 (enExample)
EP (1) EP4171742A1 (enExample)
JP (1) JP2023531069A (enExample)
KR (1) KR20230026490A (enExample)
CN (1) CN116547299A (enExample)
AU (1) AU2021295605A1 (enExample)
BR (1) BR112022026359A2 (enExample)
CA (1) CA3187785A1 (enExample)
IL (1) IL299215A (enExample)
TW (2) TWI916375B (enExample)
WO (1) WO2021260193A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2024015951A2 (en) * 2022-07-15 2024-01-18 Seq Biomarque, Llc Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease
CN117624357B (zh) * 2024-01-26 2024-03-22 南京诺唯赞医疗科技有限公司 p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536645A (ja) * 2012-10-15 2015-12-24 メディミューン リミテッド アミロイドβに対する抗体
JP2016535283A (ja) * 2013-10-24 2016-11-10 ナノソミックス・インコーポレイテッドＮａｎｏＳｏｍｉＸ， Ｉｎｃ． アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法
JP2019511500A (ja) * 2016-03-15 2019-04-25 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミロイドベータの蓄積に関連する障害の処置のためのｂａｃｅ阻害剤と抗体または抗原結合性断片との組合せ
JP2019516106A (ja) * 2016-05-06 2019-06-13 ナノソミックス・インコーポレイテッドＮａｎｏＳｏｍｉＸ， Ｉｎｃ． アルツハイマー病および他の神経変性障害のシナプスタンパク質バイオマーカーおよび鑑別診断
JP2020513570A (ja) * 2016-11-10 2020-05-14 ブレイン バイオマーカー ソリューションズ イン ヨーテボリ アーベーＢｒａｉｎ Ｂｉｏｍａｒｋｅｒ Ｓｏｌｕｔｉｏｎｓ ｉｎ Ｇｏｔｈｅｎｂｕｒｇ ＡＢ 神経変性疾患を発症するリスクがある個体を検出する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151A (en) 1837-03-25 Spring-saddle
US5654A (en) 1848-06-27 Door-spring
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
ES2276405T3 (es) 1995-06-02 2007-06-16 Gilead Sciences, Inc. Ligandos de oligonucleotidos de alta afinidad a pdgf.
US8481277B2 (en) * 2007-08-21 2013-07-09 Washington University Alzheimer's diagnosis
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
JP6949102B2 (ja) * 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536645A (ja) * 2012-10-15 2015-12-24 メディミューン リミテッド アミロイドβに対する抗体
JP2016535283A (ja) * 2013-10-24 2016-11-10 ナノソミックス・インコーポレイテッドＮａｎｏＳｏｍｉＸ， Ｉｎｃ． アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法
JP2019511500A (ja) * 2016-03-15 2019-04-25 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミロイドベータの蓄積に関連する障害の処置のためのｂａｃｅ阻害剤と抗体または抗原結合性断片との組合せ
JP2019516106A (ja) * 2016-05-06 2019-06-13 ナノソミックス・インコーポレイテッドＮａｎｏＳｏｍｉＸ， Ｉｎｃ． アルツハイマー病および他の神経変性障害のシナプスタンパク質バイオマーカーおよび鑑別診断
JP2020513570A (ja) * 2016-11-10 2020-05-14 ブレイン バイオマーカー ソリューションズ イン ヨーテボリ アーベーＢｒａｉｎ Ｂｉｏｍａｒｋｅｒ Ｓｏｌｕｔｉｏｎｓ ｉｎ Ｇｏｔｈｅｎｂｕｒｇ ＡＢ 神経変性疾患を発症するリスクがある個体を検出する方法

Also Published As

Publication number Publication date
TW202619748A (zh) 2026-05-16
BR112022026359A2 (pt) 2023-01-17
KR20230026490A (ko) 2023-02-24
TW202216188A (zh) 2022-05-01
US20230287092A1 (en) 2023-09-14
AU2021295605A1 (en) 2023-02-16
IL299215A (en) 2023-02-01
CN116547299A (zh) 2023-08-04
CA3187785A1 (en) 2021-12-30
EP4171742A1 (en) 2023-05-03
TWI916375B (zh) 2026-03-01
WO2021260193A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US20230287092A1 (en) Prevention of axonal damage using antibody binding to amyloid beta 1-42
JP6290212B2 (ja) タウオパチーの処置方法
JP6293731B2 (ja) ヒト化タウ抗体
CN101421303B (zh) 改进的初原纤维选择性抗体及其用途
KR102763164B1 (ko) 개선된 Aβ 프로토피브릴 결합 항체
US8343493B2 (en) Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs
CA3095443A1 (en) Antibody-based methods of detecting and treating alzheimer's disease
CN106659759A (zh) 人源化抗tau抗体
CN107074937A (zh) 人源抗亨廷顿蛋白（htt）抗体及其用途
US20240059766A1 (en) Tau binding compounds
EP3956027A1 (en) Novel molecules for therapy and diagnosis
US12351623B2 (en) Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates
US20210139568A1 (en) Antibody-based methods of detecting and treating alzheimer's disease
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
KR20220076658A (ko) Aimp2 및/또는 aimp2 응집체에 특이적으로 결합하는 항체
EP4458860A1 (en) Antibody specifically binding to asm, and use thereof
CA3148562A1 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
TW202434629A (zh) 以抗類澱粉β (ABETA)抗體治療神經病症之方法
BR122025021109A2 (pt) Uso de um elemento de ligação que se liga seletivamente ao peptídeo beta amiloide 1-42 humano, método para avaliar a eficácia do uso, método para identificar um paciente como adequado para o uso, e kit
JP2018508193A (ja) メディンを認識する抗体
EA051573B1 (ru) АНТИТЕЛА К ПИРОГЛУТАМАТ-β-АМИЛОИДУ И ИХ ПРИМЕНЕНИЕ
HK40071061A (en) Novel molecules for therapy and diagnosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251031

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260806